Due to anticompetitive practices, the United States lags Germany and Switzerland in the number of biosimilars on the market, while also having substantially higher prices for both biosimilars and reference products.
Compared with Germany and Switzerland, biosimilars were slower to come to the market in the United States between 2011 and 2020, which indicates a need in the United States for policies targeting anticompetitive practices, according to a study published in JAMA Network Open.
Since biosimilars have the capability of spurring competition against expensive biologics, and thus, lowering prices, countries have developed policies to help get biosimilars to market. “However, studies have shown that there are varying policies and biosimilar uptake in European countries and that the observed levels of competition and uptake have not reached the expected levels in the US,” the authors wrote.
Researchers from the University of Zurich, London School of Economics and Political Science, and the Drug Commission of the German Medical Association assessed uptake and prices of biosimilars in the United States and compared them with Germany and Switzerland, which have national drug price negotiation mechanisms in place.
They used publicly available databases to identify all reference biologics and biosimilars that were approved in the 3 countries through August 2020. Prices from January 1, 2011, to December 31, 2020, were assessed.
There were some differences between the United States and European countries in the qualification of biosimilars:
A total of 15 biosimilars and 6 reference products were included for the United States, 52 biosimilars and 15 reference products for Germany, and 28 biosimilars and 13 reference products for Switzerland. The United States analysis did not include products including enoxaparin sodium, filgrastim, teriparatide, insulin glargine, and insulin lispro because they were not approved through the biosimilars pathway. In addition, adalimumab and etanercept biosimilars were excluded since none of them have launched yet due to legal disputes.
In the United States, bevacizumab uptake was highest 1 year after market entry at 36%, while infliximab had the lowest uptake after 1 year at just 3%. In Germany, adalimumab uptake was highest (48%) and insulin lispro (2%) was lowest after 1 year on the market. In Switzerland, rituximab had the highest uptake (25%), while insulin glargine (1%) had the lowest after 1 year.
In a comparison of the 6 products on the market with at least 1 biosimilar in all 3 countries, the researchers found that while market share was highest in Germany, it grew at a faster rate in the United States.
“Biosimilars in the US that entered the market more recently were estimated to experience a faster uptake (as measured by the market share 1 year after launch), whereas in Germany and Switzerland the coefficients were small and not significant,” the researchers noted.
Prices for biosimilars varied greatly across the 3 countries. In the United States, biosimilars had relative prices that were between 55% and 90% that of the reference products. In Switzerland, biosimilars also had lower prices at market entry with prices ranging between 70% and 90% of the reference price. However, in Germany, trastuzumab and pegfilgrastim biosimilars actually entered the market at higher prices compared with the reference products. For the remaining biosimilar products entering the German market, relative prices were between 65% and 100% of the reference price.
For the 6 products with biosimilars in all 3 countries, the United States and Switzerland had similar relative prices. Prices were highest in Germany.
Monthly treatment costs were higher than the costs in Germany and Switzerland. Median monthly treatment costs per patient were $8987 for biosimilars in the United States compared with $932 in Germany and $1351 in Switzerland. The median monthly treatment costs for reference products were $11,503 in the United States compared with $1285 in Germany and $1801 in Switzerland.
“Policies for drug pricing negotiations in the US against anticompetitive practices of exclusionary contracts could allow biosimilars to enter the market sooner and at lower costs, which could result in lower health care costs and improved patient access,” the authors concluded.
Reference
Carl DL, Laube Y, Serra-Burriel M, Naci H, Ludwig W-D, Vokinger KN. Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland. JAMA Netw Open. 2022;5(12):e2244670. doi:10.1001/jamanetworkopen.2022.44670
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More